Cell and Gene Commercialization

  1. What LSPA's Life Sciences Future Says About The Road Ahead For CGT 10/2/2026

    The LSPA’s Life Sciences Future 2026 highlighted how shifting capital, M&A, global competition, and commercial pressures are reshaping CGT.

  2. Inside Scaling Next-Gen MSCs Without Scaling Risk 9/25/2026

    Here's why scaling MSC therapies requires maintaining product consistency, potency, and comparability as manufacturing evolves.

  3. Early Planning For CGT Commercialization: Regulatory, Manufacturing, And Market Access 9/23/2026

    Commercialization decisions in cell and gene therapy are made earlier than most manufacturers expect, with regulatory, manufacturing, and market access implications that compound over time.

  4. Structuring CGT Deals for the Long Term with Troutman Pepper Locke's EA Weeks, J.D., Ph.D. 9/22/2026

    In episode 138 of Cell & Gene: The Podcast, EA Weeks, J.D., Ph.D., Counsel at Troutman Pepper Locke talks to Host Erin Harris about the deal terms in CGT that matter most, including IP ownership, manufacturing capacity, CMC milestones, data rights, tech transfer, and more.

  5. Inside Kyverna's Autoimmune CAR T Platform Beyond SPS 9/16/2026

    Kyverna's progress suggests that autoimmune CAR T's commercial viability will depend as much on manufacturing readiness and focused indication selection as on its potential to deliver durable, drug-free remission.

  6. Optimizing The Channel Strategy For Your CGT 9/9/2026

    Build a channel strategy tailored to your cell or gene therapy. Explore distribution, provider access, and fulfillment options that can reduce complexity and improve patient access.

  7. Breaking The Bottlenecks In Regenerative Medicine Manufacturing 8/29/2026

    See how tiered automation platforms resolve cell therapy manufacturing bottlenecks, enabling a seamless transition from clinical trials to high-volume commercial supply.

  8. Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology 8/28/2026

    REVTORPYK's FDA approval highlights the broader push toward precision therapies that address complex disease biology, overcome resistance, and deliver more durable patient benefit.

  9. What Goes Into Restarting A Shelved Orphan Drug Candidate? 8/19/2026

    The Orphan Therapeutics Accelerator wants to help viable clinical-phase products reach patients. Its cofounder describes the complexity of rebooting a shelved candidate.

  10. July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing 8/7/2026

    Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.